Full PRTNCT07724808
Rewiring Chronic Pain
A study testing Pain Reprocessing Therapy (PRT) and TAU in people with Full PRT and Partial PRT (Non Somtic), run by Ben-Gurion University of the Negev at 1 site in Israel.
Trial summary
This study examines the effectiveness of a brief psychological intervention for chronic pain treatment, as well as the psychological and neurophysiological mechanisms associated with changes in pain intensity. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Full PRT, Partial PRT (Non Somtic), Treatment as Usual
- What is being tested?
- Pain Reprocessing Therapy (PRT) and TAU
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Oct 2026to Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 20-70 years
- Chronic pain lasting over 3 months, including chronic pain conditions such as fibromyalgia and complex regional pain syndrome (CRPS)
- Average pain intensity ≥4 on a 0-10 scale
- Stable medication regimen for at least 4 weeks prior to treatment initiation
- Hebrew language fluency
- Provision of informed consent, including consent for video recordings
Who cannot join
- Current participation in other pain-related psychotherapy
- Pregnancy
- Substance abuse, including deviations from prescribed medication use
- Change in medication or dosage in the 4 weeks preceding treatment
- Diagnosed active cancer
- Dementia
Show all 10Show fewer
- Severe depression (BDI-II score > 29)
- Moderate cognitive impairment based on the Montreal Cognitive Assessment (MoCA)
- Current or past diagnosis of schizophrenia, psychosis, bipolar disorder, multiple personality disorder, or dissociative identity disorder
- Inability to undergo MRI as determined by MRI safety screening (e.g., claustrophobia, metal in body such as vascular clips, pacemakers, or certain cochlear implants)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Israel1 site
Ben-Gurion University of the Negev
Beersheba
Lital Cohen-Blum, M.A., +972-522644388, cohelita@post.bgu.ac.il
About this study
Official title: Rewiring Chronic Pain: Cognitive & Somatic Therapy Meets Neuroscience
This study examines the effectiveness of a brief psychological intervention for chronic pain treatment, as well as the psychological and neurophysiological mechanisms associated with changes in pain intensity.
Participants with chronic pain will be randomly assigned to one of three groups: two types of brief psychological interventions and a treatment-as-usual control group. Throughout the study, participants will attend a series of therapeutic sessions, complete questionnaires, undergo brain measurements (EEG and MRI), and participate in physiological monitoring using a smartwatch.
Read more
The study aims to investigate which cognitive and physiological changes occur during the intervention, and whether early markers can be identified that may predict improvement in pain following this type of treatment. In addition, differences between cognitive and somatic components of the intervention will be examined to better understand which elements contribute to clinical change, and to determine whether knowledge alone is sufficient or whether participants must undergo a bodily experience in order to produce changes in pain levels.
The goal of the study is to improve understanding of the mechanisms underlying chronic pain and responses to psychological treatments, and to contribute to the development of more personalized, effective treatments with minimal side effects in the future.
Read the detailed description
Chronic pain is estimated to affect 30% of adults and remains poorly managed by pharmacological approaches, which yield only modest pain reductions (~0.7-0.9 points on a 0-10 scale) and carry risks of sedation, misuse, and dependence. Short-term psychological interventions, particularly Pain Reprocessing Therapy (PRT), have shown large effects in randomized trials, yet the mechanisms driving their efficacy, and the specific contributions of cognitive versus somatic components, remain unclear.
Chronic pain has been consistently associated with structural and functional brain alterations in regions supporting sensory, affective, and interoceptive processing, including the ventromedial prefrontal cortex, anterior cingulate cortex, insula, and nucleus accumbens. Contemporary frameworks (e.g., the dynamic pain connectome) conceptualize chronic pain as a disorder of distributed network dysregulation rather than isolated regional dysfunction, motivating whole-brain functional connectivity, gray matter, and white matter analyses. At the electrophysiological level, slow-wave EEG activity, particularly theta (4-8 Hz) and alpha (8-12 Hz) power, has been linked to low-arousal states induced by hypnosis and mindfulness meditation, both of which produce clinical pain reduction. Animal evidence further links theta activity to neuroplasticity. On this basis, we hypothesize that arousal-state shifts indexed by EEG slow-wave activity and HRV coherence during PRT sessions will predict clinical improvement, and that pre-post MRI will reveal corresponding network and structural changes.
The proposed study is a single-blind, three-arm randomized controlled trial that will compare: (1) Full PRT integrating cognitive (psychoeducation) and somatic components (see full protocol at www.painreprocessingtherapy.com/wp-content/uploads/2024/10/PRT-Group-Protocol.pdf); (2) Partial PRT delivering only the cognitive component; and (3) Treatment as Usual (TAU). Both intervention arms will consist of eight 60-minute individual in-person sessions delivered twice weekly by trained providers, with real-time EEG monitoring during each session accessible to the provider to dynamically inform the therapeutic process. Randomization will be stratified by age and medication use, and participants will also be randomly assigned across providers to prevent provider-related confounding. A pilot phase (3-5 participants per intervention arm) will be conducted with EEG but without MRI to refine procedures.
Home practice will be standardized within each arm via a unified 8-10 minute audio recording: somatic tracking for the Full PRT arm, and an external-attention mindfulness exercise (sounds, smells, and visual imagery, deliberately avoiding bodily focus) for the Partial PRT arm, isolating the somatic component. Adherence will be self-reported. Assessment will occur at baseline, mid-treatment (abbreviated battery), post-treatment, and at follow-up (MRI up to 6 months; questionnaires up to 5 years). Twice-daily pain ratings and pre/post-session relaxation and valence ratings (0-10) will be collected throughout treatment.
Multimodal physiological and neural data will be collected as follows. MRI scans (pre- and post-treatment, ~40 min each) will include high-resolution T1-weighted anatomical imaging, resting-state fMRI, diffusion MRI, and 10 minutes of naturalistic audio-guided fMRI (5 min somatic tracking, 5 min neutral book chapter audio, both with eyes-closed via noise-cancelling headphones). EEG will be recorded during every intervention session using the g.tec Unicorn BCI Core-8 (8 channels, flexible montage). Continuous physiological monitoring via Garmin Vivosmart 5 wearables will capture heart rate variability (beat-to-beat intervals), sleep architecture, and daily activity levels for up to 6 weeks. Blood and saliva samples may also be collected.
Analyses will be conducted in Python. Clinical and physiological outcomes will be modeled using Bayesian mixed-effects general linear models to test whether markers of low-arousal states (EEG alpha/theta activity and HRV coherence) predict pain reduction, accounting for repeated measures and covariates. fMRI data will be preprocessed with fMRIPrep and analyzed using parcellation-based connectivity and Network-Based Statistic; structural MRI with FreeSurfer (gray matter volume); diffusion MRI with DIPY (fractional anisotropy); naturalistic fMRI with voxelwise encoding models; and EEG with MNE-Python. Exploratory multivariate prediction of clinical response will use machine learning classifiers.
- Conditions
- Full PRT, Partial PRT (Non Somtic), Treatment as Usual
- Being tested
- Pain Reprocessing Therapy (PRT), TAU
- Keywords
- chronic pain, resting-state fMRI, Pain Reprocessing Therapy (PRT), naturalistic neuroimaging, Network Based Statistic (NBS), functional connectivity, fMRI
- Medical subject headings
- Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pain Reprocessing Therapy (PRT)Behavioural
Also called PRT, Partial PRT
In this full PRT, the participants will receive pain reprocessing therapy twice a week for four weeks (a total of 8 sessions). This treatment focuses on psychoeducation, cognitive restructuring and somatic elements.
In the Partial PRT, participants will receive the same intervention, but without the somatic element.
TAUOther
Participants in this arm will receive treatment as usual.
| Study group | Role | What they receive |
|---|---|---|
| Treatment as Usual | Active comparator | This arm includes receiving the TAU treatment in chronic pain (oral medications and/or physical therapy). Receives: Other: TAU |
| Pain Reprocessing Therapy (PRT) | Experimental | In this condition, the participants will receive pain reprocessing therapy twice a week for four weeks (a total of 8 sessions). This treatment focuses on psychoeducation, cognitive restructuring and somatic elements. Receives: Behavioral: Pain Reprocessing Therapy (PRT) |
| Partial PRT | Experimental | In this condition, participants will receive partial PRT, which includes psychoeducation and cognitive restructuring. Receives: Behavioral: Pain Reprocessing Therapy (PRT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average pain intensity in the first week post-treatment
Participants will be prompted twice daily via the Labfront app, connected to their wearable, to respond to the following single item from the Brief Pain Inventory (BPI): "Please rate your pain by circling the one number that tells how much pain you have right now," rated on a 0-10 numeric scale (0 = "No pain"; 10 = "Pain as bad as you can imagine"). Prompts will be delivered during 6 weeks, where the primary outcome will be the mean of all valid responses collected during the first week post-treatment.
Measured: Twice a day for 6 weeks
Secondary outcomes (13)
Pain severity: pre- to post-treatment score difference
Score of pain severity from Brief Pain Inventory- short form (average of items 3-6)
Measured: 4 weeks of treatment
Pain interference: pre- to post-treatment score difference
Score of pain interference from Brief Pain Inventory- short form (average of items 9A-9G)
Measured: 4 weeks of treatment
Pain levels (0-10) at up to 6 months follow-up
Participants will complete the Brief Pain Inventory (BPI) questionnaire, which includes the item: "Please rate your pain by circling the one number that best describes your pain on average (in the last week)," rated on a 0-10 numeric scale (0 = "No pain"; 10 = "Pain as bad as you can imagine"). The response to this item will serve as a secondary outcome measure of average pain intensity over the preceding week, assessed at up to 6-month follow-up.
Measured: Up to 6 months post-treatment
Anxiety levels: pre- to post-treatment difference
Score of Generalized Anxiety Disorder questionnaire (GAD-7)
Measured: 4 weeks of treatment
Depression levels: pre- to post-treatment difference
Score of the questionnaire Beck depression inventory || (BDI-II)
Measured: 4 weeks of treatment
Sleep quality- wearables
Assessing sleep quality using smartwatches
Measured: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).
Sleep quality: pre- to post-treatment questionnaire score difference
Difference in scores of Insomnia Severity Index (ISI)
Measured: 4 weeks of treatment
Self-rated health: pre- to post-treatment questionnaire score difference
Difference in score of the Short Form Survey (SF-12) questionnaire
Measured: 4 weeks of treatment
Pain catastrophizing: pre- to post-treatment score difference
Difference in score of Pain Catastrophizing Scale (PCL) questionnaire
Measured: 4 weeks of treatment
Emotional regulation: pre- to post-treatment score difference
Difference in score of the Emotional Regulation Questionnaire (ERQ)
Measured: 4 weeks of treatment
Causal attribution: change form pre- to post-treatment
Potential shift from words that are associated with body structure and positions to ones that are associated with mind, emotions and cognition.
Measured: 4 weeks of treatment
Heart Rate Variability (HRV)- wearables
Assessing HRV using smartwatches
Measured: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).
Movement- wearables
Assessing movement, including number of steps per day, using smartwatches
Measured: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2026
- Study start1 Oct 2026 (estimated)
- Primary completionDec 2029 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Full PRTStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ben-Gurion University of the Negev
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Or Duek, Ben-Gurion University of the Negev
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07724808
- Sponsor's protocol ID
- SOR-26-0181
- Status last verified
- Jul 2026
- First submitted
- 28 Jun 2026
- Last updated
- 24 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will de-identify the information and allow access to all data elements (except identifying data)
Publications
Ashar YK, Gordon A, Schubiner H, Uipi C, Knight K, Anderson Z, Carlisle J, Polisky L, Geuter S, Flood TF, Kragel PA, Dimidjian S, Lumley MA, Wager TD. Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Jan 1;79(1):13-23. doi: 10.1001/jamapsychiatry.2021.2669.
PubMed 34586357
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rewiring Chronic Pain: Cognitive & Somatic Therapy Meets Neuroscience
- ClinicalTrials.gov ID
- NCT07724808
- Acronym / sponsor ID
- SOR-26-0181
- Conditions
- Full PRT, Partial PRT (Non Somtic), Treatment as Usual
- Keywords
- chronic pain, resting-state fMRI, Pain Reprocessing Therapy (PRT), naturalistic neuroimaging, Network Based Statistic (NBS), functional connectivity, fMRI
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Ben-Gurion University of the NegevUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- Dec 2029 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 24 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study examines the effectiveness of a brief psychological intervention for chronic pain treatment, as well as the psychological and neurophysiological mechanisms associated with changes in pain intensity.
Participants with chronic pain will be randomly assigned to one of three groups: two types of brief psychological interventions and a treatment-as-usual control group. Throughout the study, participants will attend a series of therapeutic sessions, complete questionnaires, undergo brain measurements (EEG and MRI), and participate in physiological monitoring using a smartwatch.
The study aims to investigate which cognitive and physiological changes occur during the intervention, and whether early markers can be identified that may predict improvement in pain following this type of treatment. In addition, differences between cognitive and somatic components of the intervention will be examined to better understand which elements contribute to clinical change, and to determine whether knowledge alone is sufficient or whether participants must undergo a bodily experience in order to produce changes in pain levels.
The goal of the study is to improve understanding of the mechanisms underlying chronic pain and responses to psychological treatments, and to contribute to the development of more personalized, effective treatments with minimal side effects in the future.
Detailed description
Chronic pain is estimated to affect 30% of adults and remains poorly managed by pharmacological approaches, which yield only modest pain reductions (~0.7-0.9 points on a 0-10 scale) and carry risks of sedation, misuse, and dependence. Short-term psychological interventions, particularly Pain Reprocessing Therapy (PRT), have shown large effects in randomized trials, yet the mechanisms driving their efficacy, and the specific contributions of cognitive versus somatic components, remain unclear.
Chronic pain has been consistently associated with structural and functional brain alterations in regions supporting sensory, affective, and interoceptive processing, including the ventromedial prefrontal cortex, anterior cingulate cortex, insula, and nucleus accumbens. Contemporary frameworks (e.g., the dynamic pain connectome) conceptualize chronic pain as a disorder of distributed network dysregulation rather than isolated regional dysfunction, motivating whole-brain functional connectivity, gray matter, and white matter analyses. At the electrophysiological level, slow-wave EEG activity, particularly theta (4-8 Hz) and alpha (8-12 Hz) power, has been linked to low-arousal states induced by hypnosis and mindfulness meditation, both of which produce clinical pain reduction. Animal evidence further links theta activity to neuroplasticity. On this basis, we hypothesize that arousal-state shifts indexed by EEG slow-wave activity and HRV coherence during PRT sessions will predict clinical improvement, and that pre-post MRI will reveal corresponding network and structural changes.
The proposed study is a single-blind, three-arm randomized controlled trial that will compare: (1) Full PRT integrating cognitive (psychoeducation) and somatic components (see full protocol at www.painreprocessingtherapy.com/wp-content/uploads/2024/10/PRT-Group-Protocol.pdf); (2) Partial PRT delivering only the cognitive component; and (3) Treatment as Usual (TAU). Both intervention arms will consist of eight 60-minute individual in-person sessions delivered twice weekly by trained providers, with real-time EEG monitoring during each session accessible to the provider to dynamically inform the therapeutic process. Randomization will be stratified by age and medication use, and participants will also be randomly assigned across providers to prevent provider-related confounding. A pilot phase (3-5 participants per intervention arm) will be conducted with EEG but without MRI to refine procedures.
Home practice will be standardized within each arm via a unified 8-10 minute audio recording: somatic tracking for the Full PRT arm, and an external-attention mindfulness exercise (sounds, smells, and visual imagery, deliberately avoiding bodily focus) for the Partial PRT arm, isolating the somatic component. Adherence will be self-reported. Assessment will occur at baseline, mid-treatment (abbreviated battery), post-treatment, and at follow-up (MRI up to 6 months; questionnaires up to 5 years). Twice-daily pain ratings and pre/post-session relaxation and valence ratings (0-10) will be collected throughout treatment.
Multimodal physiological and neural data will be collected as follows. MRI scans (pre- and post-treatment, ~40 min each) will include high-resolution T1-weighted anatomical imaging, resting-state fMRI, diffusion MRI, and 10 minutes of naturalistic audio-guided fMRI (5 min somatic tracking, 5 min neutral book chapter audio, both with eyes-closed via noise-cancelling headphones). EEG will be recorded during every intervention session using the g.tec Unicorn BCI Core-8 (8 channels, flexible montage). Continuous physiological monitoring via Garmin Vivosmart 5 wearables will capture heart rate variability (beat-to-beat intervals), sleep architecture, and daily activity levels for up to 6 weeks. Blood and saliva samples may also be collected.
Analyses will be conducted in Python. Clinical and physiological outcomes will be modeled using Bayesian mixed-effects general linear models to test whether markers of low-arousal states (EEG alpha/theta activity and HRV coherence) predict pain reduction, accounting for repeated measures and covariates. fMRI data will be preprocessed with fMRIPrep and analyzed using parcellation-based connectivity and Network-Based Statistic; structural MRI with FreeSurfer (gray matter volume); diffusion MRI with DIPY (fractional anisotropy); naturalistic fMRI with voxelwise encoding models; and EEG with MNE-Python. Exploratory multivariate prediction of clinical response will use machine learning classifiers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Treatment as Usual | Active comparator | Other: TAUThis arm includes receiving the TAU treatment in chronic pain (oral medications and/or physical therapy). |
| Pain Reprocessing Therapy (PRT) | Experimental | Behavioral: Pain Reprocessing Therapy (PRT)In this condition, the participants will receive pain reprocessing therapy twice a week for four weeks (a total of 8 sessions). This treatment focuses on psychoeducation, cognitive restructuring and somatic elements. |
| Partial PRT | Experimental | Behavioral: Pain Reprocessing Therapy (PRT)In this condition, participants will receive partial PRT, which includes psychoeducation and cognitive restructuring. |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 20-70 years
- Chronic pain lasting over 3 months, including chronic pain conditions such as fibromyalgia and complex regional pain syndrome (CRPS)
- Average pain intensity ≥4 on a 0-10 scale
- Stable medication regimen for at least 4 weeks prior to treatment initiation
- Hebrew language fluency
Key exclusion criteria (10 listed)
- Current participation in other pain-related psychotherapy
- Pregnancy
- Substance abuse, including deviations from prescribed medication use
- Change in medication or dosage in the 4 weeks preceding treatment
- Diagnosed active cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pain Reprocessing Therapy (PRT)Also: PRT, Partial PRTIn this full PRT, the participants will receive pain reprocessing therapy twice a week for four weeks (a total of 8 sessions). This treatment focuses on psychoeducation, cognitive restructuring and somatic elements. In the Partial PRT, participants will receive the same intervention, but without the somatic element. | Behavioural | Pain Reprocessing Therapy (PRT), Partial PRT |
| TAUParticipants in this arm will receive treatment as usual. | Other | Treatment as Usual |
Primary outcome
Average pain intensity in the first week post-treatment
Time frame: Twice a day for 6 weeks
Participants will be prompted twice daily via the Labfront app, connected to their wearable, to respond to the following single item from the Brief Pain Inventory (BPI): "Please rate your pain by circling the one number that tells how much pain you have right now," rated on a 0-10 numeric scale (0 = "No pain"; 10 = "Pain as bad as you can imagine"). Prompts will be delivered during 6 weeks, where the primary outcome will be the mean of all valid responses collected during the first week post-treatment.
13 secondary outcomes
Pain severity: pre- to post-treatment score difference
Time frame: 4 weeks of treatment
Pain interference: pre- to post-treatment score difference
Time frame: 4 weeks of treatment
Pain levels (0-10) at up to 6 months follow-up
Time frame: Up to 6 months post-treatment
Anxiety levels: pre- to post-treatment difference
Time frame: 4 weeks of treatment
Depression levels: pre- to post-treatment difference
Time frame: 4 weeks of treatment
Sleep quality- wearables
Time frame: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).
Sleep quality: pre- to post-treatment questionnaire score difference
Time frame: 4 weeks of treatment
Self-rated health: pre- to post-treatment questionnaire score difference
Time frame: 4 weeks of treatment
Pain catastrophizing: pre- to post-treatment score difference
Time frame: 4 weeks of treatment
Emotional regulation: pre- to post-treatment score difference
Time frame: 4 weeks of treatment
Causal attribution: change form pre- to post-treatment
Time frame: 4 weeks of treatment
Heart Rate Variability (HRV)- wearables
Time frame: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).
Movement- wearables
Time frame: Monitoring will be done for 6 weeks (up to one week before treatment and one week after the end of treatment).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2026.
- Background: PubMed 34586357Ashar YK, Gordon A, Schubiner H, Uipi C, Knight K, Anderson Z, Carlisle J, Polisky L, Geuter S, Flood TF, Kragel PA, Dimidjian S, Lumley MA, Wager TD. Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Jan 1;79(1):13-23. doi: 10.1001/jamapsychiatry.2021.2669.
- Individual participant dataSharing planned: Yes. We will de-identify the information and allow access to all data elements (except identifying data)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pain Reprocessing Therapy (PRT) and TAU in people with Full PRT and Partial PRT (Non Somtic), run by Ben-Gurion University of the Negev at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Or Duek, Ph.D (+972-507606547, ord@bgu.ac.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average pain intensity in the first week post-treatment (time frame: Twice a day for 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07724808, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2026.